{"id":16279,"date":"2022-06-13T20:05:41","date_gmt":"2022-06-13T18:05:41","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16279"},"modified":"2024-12-11T15:20:07","modified_gmt":"2024-12-11T14:20:07","slug":"les-car-t-apres-70-ans-dans-les-lymphomes-b-diffus-une-bonne-idee","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/les-car-t-apres-70-ans-dans-les-lymphomes-b-diffus-une-bonne-idee\/","title":{"rendered":"Les CAR T apr\u00e8s 70 ans dans les lymphomes B diffus : une bonne id\u00e9e ?"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1302px;margin-left: calc(-5% \/ 2 );margin-right: calc(-5% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.375%;--awb-margin-bottom-large:0px;--awb-spacing-left-large:2.375%;--awb-width-medium:100%;--awb-spacing-right-medium:2.375%;--awb-spacing-left-medium:2.375%;--awb-width-small:100%;--awb-spacing-right-small:2.375%;--awb-spacing-left-small:2.375%;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><div><span lang=\"EN-US\">R\u00e9f.  :HematoStat.net ; 3 (2) : R54<\/span><\/div>\n<p><span lang=\"EN-US\"><br \/><\/span><\/p>\n<div><\/div>\n<div>\n<div><i><span lang=\"EN-US\">Ram R, Grisariu S, Shargian-Alon L, Amit O, Bar-On Y, Stepensky P, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients &#8211; a matched control multicenter cohort study. Haematologica. 1 mai 2022;107(5):1111<\/span>\u2011<span lang=\"EN-US\">8.<\/span><\/i><\/div>\n<\/div>\n<div><\/div>\n<h3>R\u00e9sum\u00e9<\/h3>\n<div><\/div>\n<div>Peu de donn\u00e9es sont disponibles quant \u00e0 l\u2019utilisation des CAR T chez les patients \u00e2g\u00e9s de plus de 70 ans (elderly) et atteints d\u2019un lymphome B diffus (LBDGC) en rechute\/r\u00e9fractaire. Les auteurs rapportent leur utilisation d\u2019axi-cel et de cilta-cel depuis leur commercialisation en Isra\u00ebl en 2019. Le groupe elderly (n=41) a pu \u00eatre compar\u00e9 aux sujets &lt; 70 ans (n=41). Il n\u2019y avait pas de diff\u00e9rence dans l\u2019incidence de survenue du syndrome de relargage cytokinique et les taux de r\u00e9ponses \u00e9taient similaires.<\/div>\n<div><\/div>\n<h3>Dans nos pratiques<\/h3>\n<p>Initialement r\u00e9serv\u00e9s aux patients les plus jeunes, les traitements par cellules CAR T se d\u00e9veloppent et s\u2019invitent maintenant chez des patients plus \u00e2g\u00e9s. Cette \u00e9tude, incluaient des patients ayant pour certains des facteurs de mauvais pronostic comme un PS \u2265 2 et se rapproche de la \u00ab vie r\u00e9elle \u00bb. Si la dur\u00e9e de r\u00e9cup\u00e9ration post-traitement est plus longue, on peut esp\u00e9rer des r\u00e9sultats similaires \u00e0 ceux observ\u00e9s dans les populations plus jeunes.<\/p>\n<h3><\/h3>\n<h3><strong>Regard du biostatisticien<\/strong><\/h3>\n<p>La comparaison entre la cohorte trait\u00e9e et celle contr\u00f4le plus jeune s\u2019est faite par un <em>matching<\/em> en fonction deux param\u00e8tres connus en donn\u00e9es de vie r\u00e9elle pour pr\u00e9dire les<i><span class=\"fusion-tooltip tooltip-shortcode\" data-animation=\"\" data-delay=\"0\" data-placement=\"top\" data-title=\"crit\u00e8re de jugement clinique permettant d\u2019\u00e9valuer l\u2019impact d\u2019un ou plusieurs param\u00e8tres (aucun effet, am\u00e9lioration ou d\u00e9t\u00e9rioration), param\u00e8tre(s) pouvant \u00eatre une donn\u00e9e biologique, un traitement, etc.\" title=\"crit\u00e8re de jugement clinique permettant d\u2019\u00e9valuer l\u2019impact d\u2019un ou plusieurs param\u00e8tres (aucun effet, am\u00e9lioration ou d\u00e9t\u00e9rioration), param\u00e8tre(s) pouvant \u00eatre une donn\u00e9e biologique, un traitement, etc.\" data-toggle=\"tooltip\" data-trigger=\"hover\"><em>outcomes<\/em><i><\/span><\/i><\/i><em> outcomes<\/em><i> <\/i>\u00e9tudi\u00e9s (ici l\u2019efficacit\u00e9, toxicit\u00e9, survie, qualit\u00e9 de vie), ceci visant \u00e0 \u00e9viter au maximum tout biais lors des analyses statistiques comparants les deux groupes. Pas de diff\u00e9rence en termes de survies (globale ou sans rechute) n\u2019a \u00e9t\u00e9 observ\u00e9e en fonction de l\u2019\u00e2ge (\u00e0 noter toutefois une erreur d\u2019\u00e9chelle sur l\u2019axe y dans la courbe de PFS).<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":16280,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[],"ppma_author":[456],"class_list":["post-16279","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16279"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16279\/revisions"}],"predecessor-version":[{"id":18224,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16279\/revisions\/18224"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16279"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}